Updated business outlook available on Peregrine Pharmaceuticals

Posted by Laura Swartz

January 24, 2011 at 10:01 AM

We at Crystal are looking forward to an exciting week as we begin releasing new research in our revamped Coverage Library. This morning, we published a business update on innovative biopharmaceutical company, Peregrine Pharmaceuticals, Inc. (PPHM-NASDAQ).

Read More

Topics: New Research, biopharmaceuticals

New Research Issued on Laep Investments Ltd.

Posted by Colleen Koski

January 24, 2011 at 9:59 AM

Today we issued an updated, 44-page Executive Informational Overview® (EIO®) on Laep Investments Ltd. Laep’s Brazilian depositary receipts (BDRs) are traded on the São Paulo Stock Exchange (Bovespa) under the ticker “MILK11.” As well, the Company is listed on the Euro MTF market of the Luxembourg Stock Exchange.

Read More

Topics: New Research

Out with the old and in with the new…

Posted by Laura Swartz

January 11, 2011 at 10:05 AM

This morning, we at Crystal Research debuted a new Research Library webpage. The new page is designed to be easier to navigate and encompasses several new search tools. In addition to viewing an A to Z listing of companies under our coverage, readers can now sort by date, industry, and exchange. We have also created dedicated pages for each company listed in our portfolio. These pages present a brief overview of each firm and include all research that we have published on that firm, as well as recent press releases, stock charts, and key financials (via feeds from Yahoo! Finance).

Read More

Topics: Crystal Research Associates

A Solid Start to 2011

Posted by Colleen Koski

January 5, 2011 at 10:11 AM

As we kick off the New Year, many companies within our Coverage Universe are showing a positive start to 2011. For example, Canadian biopharmaceutical company Bioniche Life Sciences Inc. (BNC-TSX) recently raised A$12.5 million in Australia. Biotechnology company Xoma Ltd. (XOMA-NASDAQ) signed a development and licensing agreement potentially valued up to $505 million for an anti-inflammatory drug candidate. In addition, Advanced Cell Technology, Inc. ([“ACT”] ACTC-OTC.BB), a regenerative medicine company, announced that the FDA has cleared its Investigational New Drug application (IND) to test a therapy made from embryonic stem cells in patients with macular degeneration, a leading cause of vision loss. Further, the Tel-Aviv Stock Exchange (TASE) approved the inclusion of Pluristem Therapeutics Inc.’s (PSTI-NASDAQ) ordinary shares on four TASE equity indexes: Tel-Tech, TA Composite, MidCap TA, and Biomed.

Read More

Topics: Newsworthy Events, Bioniche, CEL-SCI, Pluristem Therapeutics

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic